tbuckley/cabot-search huggingface dataset:
Abstract 12212: The Impact of Heart Failure Etiology on Patients Undergoing Left Ventricular Assist Device Placement
Authors: Hossam Abubakar, Ahmed Subahi, Oluwole Adegbala, Ahmed S Yassin, Emmanuel Akintoye, Abdelrahman Ahmed, Adedotun Alade, Ahmed Abdulrahman, Mohit Pahuja, Luis Afonso
Journal: Circulation (2018)

Background: Evidence suggests that the ischemic etiology of heart failure (HF) is a predictor of mortality in patients receiving guidline directed medical therapy as well as in patients undergoing ...
Combination strategies to maximize the benefits of cancer immunotherapy
Authors: Shaoming Zhu, Tian Zhang, Lei Zheng, Hongtao Liu, Wenru Song, Delong Liu, Zihai Li, Chong-xian Pan
Journal: Journal of Hematology & Oncology (2021)

Abstract Immunotherapies such as immune checkpoint blockade (ICB) and adoptive cell therapy (ACT) have revolutionized cancer treatment, especially in patients whose disease was otherwise considered incurable. However, primary and secondary resistance to single agent immunotherapy often results in treatment failure, and only a minority of patients experience long-term benefits. This review article will discuss the relationship between cancer immune response and mechanisms of resistance to immunotherapy. It will also provide a comprehensive review on the latest clinical status of combination therapies (e.g., immunotherapy with chemotherapy, radiation therapy and targeted therapy), and discuss combination therapies approved by the US Food and Drug Administration. It will provide an overview of therapies targeting cytokines and other soluble immunoregulatory factors, ACT, virotherapy, innate immune modifiers and cancer vaccines, as well as combination therapies that exploit alternative immune targets and other therapeutic modalities. Finally, this review will include the stimulating insights from the 2020 China Immuno-Oncology Workshop co-organized by the Chinese American Hematologist and Oncologist Network (CAHON), the China National Medical Product Administration (NMPA) and Tsinghua University School of Medicine.
Posttraurnatic stress disorder and depression following traurna: Understanding comorbidity
Authors: ML O'Donnell, M Creamer, P Pattison
Journal: American Journal of Psychiatry (2004)

OBJECTIVE: Posttraumatic stress disorder (PTSD) and major depression occur frequently following traumatic exposure, both as separate disorders and concurrently. This raises the question of whether PTSD and depression are separate disorders in the aftermath of trauma or part of a single general traumatic stress construct. This study aimed to explore the relationships among PTSD, depression, and comorbid PTSD/depression following traumatic injury. METHOD: A group of 363 injury survivors was assessed just prior to discharge from hospital and 3 and 12 months postinjury. Canonical correlations were used to examine the relationship between PTSD and depression symptom severity and a set of predictor variables. Multinomial logistic regression was used to identify whether the diagnostic categories of PTSD, depression, and comorbid PTSD/depression were associated with different groups of predictors. RESULTS: The majority of psychopathology in the aftermath of trauma was best conceptualized as a general traumatic stress factor, suggesting that when PTSD and depression occur together, they reflect a shared vulnerability with similar predictive variables. However, there was also evidence that in a minority of cases at 3 months, depression occurs independently from PTSD and was predicted by a different combination of variables. CONCLUSIONS: While PTSD and comorbid PTSD/depression are indistinguishable, the findings support the existence of depression as a separate construct in the acute, but not the chronic, aftermath of trauma.
Implementation of geriatric haematology programmes for the treatment of older people with haematological malignancies in low-resource settings
Authors: Enrique Soto-Perez-de-Celis, Javier Martínez-Peromingo, Yanin Chávarri-Guerra, Kah Poh Loh, Roberta Demichelis-Gómez, Morgani Rodrigues, Fresia Yabeta, Guldane Cengiz Seval, Osman Ilhan, Raul Cordoba
Journal: The Lancet Healthy Longevity (2021)

In 2020, about 600 000 people aged 65 years and older were diagnosed with a haematological malignancy worldwide, and this number will increase to almost 1 million by 2040, with the largest growth taking place in regions with less developed economies. Health-care systems globally are ill-prepared to face this impending increase in the burden of haematological malignancies among older people, and geriatric oncology and haematology are not properly developed in most low-income and middle-income countries, as well as in many community settings in high-income countries. Here, we provide an overview of the status of geriatric haematology in resource-limited settings, with a focus on health-care systems, educational activities, availability of resource-stratified guidelines, development of clinical programmes, and ongoing research initiatives. We also provide recommendations for the future development of geriatric haematology globally, focusing on the creation of educational activities for health-care providers, fostering research initiatives, improving the inclusion of principles of geriatric care into everyday clinical practice, and building strong international and local partnerships among organisations.
Treatment-free survival after discontinuation of immune checkpoint inhibitors in metastatic renal cell carcinoma: a systematic review and meta-analysis
Authors: Alice Tzeng, Tony H Tzeng, Moshe C Ornstein
Journal: Journal for ImmunoTherapy of Cancer (2021)

While immune checkpoint inhibitors (ICI) can lead to sustained responses in metastatic renal cell carcinoma (mRCC), the optimal duration of therapy remains unknown. We aimed to examine treatment-free survival (TFS) in objective responders who discontinued ICI and to explore factors that may impact objective response rate (ORR) and TFS. MEDLINE/PubMed, Embase, and the Cochrane Library were searched for prospective studies reporting individual outcomes after ICI discontinuation in patients with mRCC. Pooled ORR and TFS were estimated using random-effects meta-analyses, and associations between ICI regimen type or treatment line and ORR or TFS were evaluated. Sixteen cohorts comprising 1833 patients treated with ICI were included. The pooled ORR was 43% (95% CI 33% to 53%), and significant differences in summary estimates existed among patients who received ICI monotherapy (22%, 95% CI 18% to 26%), ICI plus a vascular endothelial growth factor (VEGF) pathway inhibitor (57%, 95% CI 48% to 65%), and dual ICI (40%, 95% CI 36% to 44%). Of 572 responders who had available data, 327 stopped ICI, with 86 (26%) continuing to respond off-treatment. Pooled TFS rates at 6 and 12 months were 35% (95% CI 20% to 50%) and 20% (95% CI 8% to 35%), respectively, and were highest for responders treated with dual ICI and lowest for those treated with ICI plus a VEGF pathway inhibitor. Thus, a subset of patients with mRCC who are treated with ICI-based therapy can have durable TFS after therapy discontinuation. Prospective clinical trials and biomarkers are needed to identify patients who can discontinue ICI therapy without compromising clinical outcomes.
OTUB1 alleviates NASH through inhibition of the TRAF6‐ASK1 signaling pathways
Authors: Jie‐Lei Zhang, Bin‐Bin Du, Dian‐Hong Zhang, Huan Li, Ling‐Yao Kong, Guang‐Jian Fan, Ya‐Peng Li, Peng‐Cheng Li, Cui Liang, Zheng Wang, Lu‐Lu Yang, Zheng‐Yang Hao, Lei‐Ming Wu, Zhen Huang, Jian‐Zeng Dong, Jin‐Ying Zhang, Rui Yao, Shou‐Jun Wang, Yan‐Zhou Zhang
Journal: Hepatology (2021)

NAFLD is considered as the hepatic manifestation of the metabolic syndrome, which includes insulin resistance, obesity and hyperlipidemia. NASH is a progressive stage of NAFLD with severe hepatic steatosis, hepatocyte death, inflammation, and fibrosis. Currently, no pharmacological interventions specifically tailored for NASH are approved. Ovarian tumor domain, ubiquitin aldehyde binding 1 (OTUB1), the founding member of deubiquitinases, regulates many metabolism-associated signaling pathways. However, the role of OTUB1 in NASH is unclarified.
LBA13 Predictive impact of biomarkers on pCR and survival after de-escalated neoadjuvant T-DM1 with or without endocrine therapy (ET) vs. trastuzumab+ET in HER2+/HR+ early breast cancer: WSG ADAPT TP trial
Authors: N. Harbeck, U. Nitz, M. Christgen, S. Kuemmel, M. Braun, C.M. Biehl, C. Schumacher, W. Malter, B. Aktas, H. Forstbauer, J. Tio, E-M. Grischke, C. Kolberg-Liedtke, S. de Haas, R.J. Deurloo, R.E. Kates, C. Eulenburg zu, R. Wuerstlein, H. Kreipe, O. Gluz
Journal: Annals of Oncology (2021)
Elevated glutathione levels confer cellular sensitization to cisplatin toxicity
Authors: Helen Chen
Journal: Cancer Research (2007)

2324  Cisplatin (CDDP) has been recognized as an important antitumor agent since its introduction into clinical trials about three decades ago. However, many patients eventually relapse and develop resistance, representing a major limitation of platinum-based chemotherapy. Multiple mechanisms have been proposed to account for the resistance to cisplatin; and numerous studies have demonstrated that exposing cultured cells to cisplatin led to the development of CDDP resistance with concomitant increased of glutathione (GSH) levels and elevated expression of the rate-limiting enzyme of its biosynthesis, gamma glutamylcysteine synthetase (g-GCS) which consists of a heavy (catalytic) subunit (g-GCSh) and a light (regulatory) subunit. These observations led to the supposition that elevated GSH levels are associated with CDDP resistance. However, we found that elevated GSH levels (1.5- to 3.9-fold) in three g-GCSh-transfected human small cell lung cancer cell lines (SCLC) and two g-GCSh transfected rat hepatoma cell lines all exhibited elevated sensitivities to cisplatin (4.2- to 10-fold reduction in IC50). All the transfected cells exhibited elevated rates of CDDP transport due to upregulation of copper transporter (hCtr1); whereas expression of copper exporters ATP7A and ATP7B were only marginally increased. hCtr1 and ATP7A and ATP7B have been demonstrated to be cisplatin importer and exporters, respectively. Upregulation of hCtr1 in the transfected cells were not due to reduced reactive oxygene species (ROS)levels by elevated GSH expression, because SCLC cells treated with catalase which reduces intracellular ROS levels did not upregulate hCtr1 expression. Our results suggest that increased GSH levels per se are not responsible for cisplatin resistance is the drug-treated cell lines as previously thought. Rather, it may reflect a stress response phenomenon, because g-GCSh is a stress response gene.
Annals Graphic Medicine - Interconnected: A New Era of Telemedicine in the Wake of COVID-19
Authors: Urvi Bihani, Keerthi Muthukumar, Aya Khasati, Ayesha Ali, Raja Ohri, Yusuf Sheikh, Alan Hasanic
Journal: Annals of Internal Medicine (2021)

Web Exclusives5 October 2021Annals Graphic Medicine - Interconnected: A New Era of Telemedicine in the Wake of COVID-19FREEUrvi Bihani, Keerthi Muthukumar, Aya Khasati, Ayesha Ali, Raja Ohri, Yusuf Sheikh, and Alan HasanicUrvi BihaniImperial College London, London, United Kingdom (U.B., K.M., A.K., A.A., R.O., Y.S., A.H.), Keerthi MuthukumarImperial College London, London, United Kingdom (U.B., K.M., A.K., A.A., R.O., Y.S., A.H.), Aya KhasatiImperial College London, London, United Kingdom (U.B., K.M., A.K., A.A., R.O., Y.S., A.H.), Ayesha AliImperial College London, London, United Kingdom (U.B., K.M., A.K., A.A., R.O., Y.S., A.H.), Raja OhriImperial College London, London, United Kingdom (U.B., K.M., A.K., A.A., R.O., Y.S., A.H.), Yusuf SheikhImperial College London, London, United Kingdom (U.B., K.M., A.K., A.A., R.O., Y.S., A.H.), and Alan HasanicImperial College London, London, United Kingdom (U.B., K.M., A.K., A.A., R.O., Y.S., A.H.)Author, Article, and Disclosure Informationhttps://doi.org/10.7326/G21-0050 SectionsAboutVisual AbstractPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Download figure Download PowerPoint Author, Article, and Disclosure InformationAuthors: Urvi Bihani; Keerthi Muthukumar; Aya Khasati; Ayesha Ali; Raja Ohri; Yusuf Sheikh; Alan HasanicAffiliations: Imperial College London, London, United Kingdom (U.B., K.M., A.K., A.A., R.O., Y.S., A.H.)Disclosures: Authors have reported no disclosures of interest. Forms can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=G21-0050.Author/Illustrator Information: Urvi Bihani is a medical student and artist (e-mail, bihani.urvi@gmail.com; Instagram, www.instagram.com/urvi.inks); and Keerthi Muthukumar (e-mail, km1117@ic.ac.uk), Aya Khasati (e-mail, aya.khasati17@imperial.ac.uk), Ayesha Ali (e-mail, ayesha.ali17@imperial.ac.uk), Raja Ohri (e-mail, raja.ohri20@imperial.ac.uk), Yusuf Sheikh (e-mail, yusuf.sheikh20@imperial.ac.uk), and Alan Hasanic (e-mail, alan.hasanic20@imperial.ac.uk) are medical students.This article was published at Annals.org on 5 October 2021. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics October 2021Volume 174, Issue 10Page: W94-W95 ePublished: 5 October 2021 Issue Published: October 2021 Copyright & PermissionsCopyright © 2021 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
Reducing the Risk of Stroke
Authors: Albert Fournier, Roxana Oprisiu, Michel Andrejak, Jean Michel Achard, Leonardo Fernandez
Journal: JAMA (2003)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Unhappy workers communicate with less compassion and less professionalism
Authors: Emily L Russell
Journal: BMJ (2021)

Mathew and Oliver raise the uncomfortable but necessary notions that the workplace is not always joyful and that our organisations fall short of their mission statements.12 These do not sit easily with media narratives of “NHS superheroes” all pulling together.

We are familiar with “moral injury,” particularly with reference to being aware of the vast unmet healthcare need. Less familiar is the moral injury caused to healthcare workers by barriers in …
Chilblains during lockdown are associated with household exposure to SARS-CoV-2: a multicentre case–control study
Authors: Florence Poizeau, Emmanuel Oger, Sébastien Barbarot, Yannick Le Corre, Mahtab Samimi, Emilie Brenaut, Hélène Aubert, Estel Chambrelan, Catherine Droitcourt, Valérie Gissot, Christopher Heslan, Claire Laurent, Ludovic Martin, Laurent Misery, Pierre Tattevin, Alexis Toubel, Vincent Thibault, Alain Dupuy
Journal: Clinical Microbiology and Infection (2021)
1232P Understanding the diagnostic and treatment landscape in EGFRm advanced non-small cell lung cancer (aNSCLC) patients with exon 20 insertion mutations (Ex20ins)
Authors: H. Bailey, F. Nasirova, J. Sermon, B. Rodrigues, K. Khela, J. Hall, M.J. Last, J. Penton
Journal: Annals of Oncology (2021)
Extracorporeal membrane oxygenation for COVID-19: evolving outcomes from the international Extracorporeal Life Support Organization Registry
Authors: Ryan P Barbaro, Graeme MacLaren, Philip S Boonstra, Alain Combes, Cara Agerstrand, Gail Annich, Rodrigo Diaz, Eddy Fan, Katarzyna Hryniewicz, Roberto Lorusso, Matthew L Paden, Christine M Stead, Justyna Swol, Theodore J Iwashyna, Arthur S Slutsky, Daniel Brodie
Journal: The Lancet (2021)
形質膜標的光線力学的腫瘍治療のためのエピジェネティクスにヒントを得た光増感剤修飾【JST・京大機械翻訳】
Authors: Cheng Hong, Fan Gui-Ling, Fan Jing-Hao, Yuan Ping, Deng Fu-An, Qiu Xiao-Zhong, Yu Xi-Yong, Li Shi-Ying
Journal: Biomaterials (2019)
441P A study of vemurafenib and cetuximab in combination with FOLFIRI for patients with BRAF V600E-mutated advanced colorectal cancer (NCT03727763): Preliminary results
Authors: Z. Wang, Y-S. Zang, C-Y. Ye, M-M. Wang, L-Y. Yuan, W-P. Dai, L. Sun
Journal: Annals of Oncology (2021)
930TiP innovaTV 207: New dosing cohort in the open label phase II study of tisotumab vedotin in solid tumors
Authors: D. Hong, J. Fayette, A. Birnbaum, C. Steuer, M.H. Taylor, T.J. George, J. Lacy, F. Beca, L.V. Nicacio, I. Soumaoro, M. Cho
Journal: Annals of Oncology (2021)
LBA62 Efficacy and safety of tanezumab in subjects with cancer pain predominantly due to bone metastasis receiving background opioid therapy
Authors: M. Fallon, M. Sopata, E. Dragon, M.T. Brown, L. Viktrup, C.R. West, K. Hamlett, W. Bao, A. Agyemang
Journal: Annals of Oncology (2021)
1773P Anti-PD1-induced acute interstitial pneumonitis is characterized by alveolar infiltration of PD-1+CD38+TIGIT+ cytotoxic effector CD8+ T cells and CD206+ inflammatory macrophages
Authors: F-X. Danlos, A-G. Goubet, M. Aglave, A. Alfaro, B. Job, M. Francillette, A. Hanna, P. Pradere, S. Dolidon, Y. Lecluse, N. Droin, M. Deloger, B. Besse, C. Robert, J-M. Michot, J-C. Soria, F. Barlesi, L. Zitvogel, A. Marabelle, J. Le Pavec
Journal: Annals of Oncology (2021)
An artificial intelligence model to predict hepatocellular carcinoma risk in Korean and Caucasian patients with chronic hepatitis B
Authors: Hwi Young Kim, Pietro Lampertico, Joon Yeul Nam, Hyung-Chul Lee, Seung Up Kim, Dong Hyun Sinn, Yeon Seok Seo, Han Ah Lee, Soo Young Park, Young-Suk Lim, Eun Sun Jang, Eileen L. Yoon, Hyoung Su Kim, Sung Eun Kim, Sang Bong Ahn, Jae-Jun Shim, Soung Won Jeong, Yong Jin Jung, Joo Hyun Sohn, Yong Kyun Cho, Dae Won Jun, George N. Dalekos, Ramazan Idilman, Vana Sypsa, Thomas Berg, Maria Buti, Jose Luis Calleja, John Goulis, Spilios Manolakopoulos, Harry L.A. Janssen, Myoung-jin Jang, Yun Bin Lee, Yoon Jun Kim, Jung-Hwan Yoon, George V. Papatheodoridis, Jeong-Hoon Lee
Journal: Journal of Hepatology (2021)
1388P Efficacy of second line immunotherapy in advanced upper gastrointestinal tract malignancies: A pooled analysis of randomized clinical trials
Authors: P. Ntellas, K.V. Kamposioras, I. Gazouli, K. Dadouli, T. Germataki, G. Zarkavelis, A.L. Amylidi, S. Gkoura, L. Mavroeidis, F.L. Kostadima, A. Sotirios Papadaki, E. Kampletsas, D. Petrakis, M. Tolia, D. Mauri
Journal: Annals of Oncology (2021)
572P Potential impact of molecularly-selected treatment in patients with endocrine neoplasms at a tertiary university hospital
Authors: J. Pozas, M. San Roman, J. Molina-Cerrillo, I. Ruz Caracuel, H. Pian, P. Valderrábano, J. Gómez Ramírez, T. Caniego Casas, D. Pizarro, P. Gajate Borau, V. Albarrán Fernández, D.I. Rosero Rodríguez, J. Chamorro, P. Alvarez Ballesteros, I. Orejana Martin, L. Sanz, E. Grande, A. Carrato Mena, P. Garrido Lopez, T. Alonso-Gordoa
Journal: Annals of Oncology (2021)
1596P SERONCOVID: Seroconversion in solid-tumor cancer patients (p) after COVID-19 diagnosis
Authors: A. Pous, E. Felip, O. Etxaniz Ulazia, A. Hernández, S. España, M. Romeo Marin, T. Moran, J.G. Molina, G. Fernandez, D.J. Pinato, A.M. Esteve, R. Mesía
Journal: Annals of Oncology (2021)
962MO A phase I clinical trial on intratumoral injection of autologous CD1c (BDCA-1)+/CD141 (BDCA-3)+ myeloid dendritic cells (myDC) in combination with talimogene laherparepvec (T-VEC) in patients with advanced pretreated melanoma
Authors: J.K. Schwarze, J. Tijtgat, G. Awada, L. Cras, I. Dufait, R. Forsyth, I. Van Riet, S. Tuyaerts, B. Neyns
Journal: Annals of Oncology (2021)
DNA methylation-based prognostic subtypes of chordoma tumors in tissue and plasma
Authors: Jeffrey A Zuccato, Vikas Patil, Sheila Mansouri, Jeffrey C Liu, Farshad Nassiri, Yasin Mamatjan, Ankur Chakravarthy, Shirin Karimi, Joao Paulo Almeida, Anne-Laure Bernat, Mohammed Hasen, Olivia Singh, Shahbaz Khan, Thomas Kislinger, Namita Sinha, Sébastien Froelich, Homa Adle-Biassette, Kenneth D Aldape, Daniel D De Carvalho, Gelareh Zadeh
Journal: Neuro-Oncology (2021)

Chordomas are rare malignant bone cancers of the skull-base and spine. Patient survival is variable and not reliably predicted using clinical factors or molecular features. This study identifies prognostic epigenetic chordoma subtypes that are detected noninvasively using plasma methylomes.Methylation profiles of 68 chordoma surgical samples were obtained between 1996 and 2018 across three international centers along with matched plasma methylomes where available.Consensus clustering identified two stable tissue clusters with a disease-specific survival difference that was independent of clinical factors in a multivariate Cox analysis (HR = 14.2, 95%CI: 2.1-94.8, P = 0.0063). Immune-related pathways with genes hypomethylated at promoters and increased immune cell abundance were observed in the poor-performing "Immune-infiltrated" subtype. Cell-to-cell interaction plus extracellular matrix pathway hypomethylation and higher tumor purity were observed in the better-performing "Cellular" subtype. The findings were validated in additional DNA methylation and RNA sequencing datasets as well as with immunohistochemical staining. Plasma methylomes distinguished chordomas from other clinical differential diagnoses by applying fifty chordoma-versus-other binomial generalized linear models in random 20% testing sets (mean AUROC = 0.84, 95%CI: 0.52-1.00). Tissue-based and plasma-based methylation signals were highly correlated in both prognostic clusters. Additionally, leave-one-out models accurately classified all tumors into their correct cluster based on plasma methylation data.Here, we show the first identification of prognostic epigenetic chordoma subtypes and first use of plasma methylome-based biomarkers to noninvasively diagnose and subtype chordomas. These results may transform patient management by allowing treatment aggressiveness to be balanced with patient risk according to prognosis.
594P Pain efficacy with radium-223 (Ra-223) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) in the PARABO observational study
Authors: H. Palmedo, H. Ahmadzadehfar, S. Eschmann, I. Selkinski, F. Straube, A. Niesen, J. Schönberger, V. Barsegian, K. Liepe, F.M. Mottaghy, R. Guan, J. Pinkert, S. Buetikofer, K. Herrmann
Journal: Annals of Oncology (2021)